Last reviewed · How we verify
MITIGLINIDE
At a glance
| Generic name | MITIGLINIDE |
|---|---|
| Drug class | mitiglinide |
| Target | Sulfonylurea receptor 1, Kir6.2 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Diabetes mellitus type 2
Common side effects
Key clinical trials
- A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants (PHASE1)
- Pharmacokinetic and Pharmacodynamic Study of Glufast Tablets 10mg(Mitiglinide) (PHASE4)
- Post-marketing Clinical Trial of KAD-1229 in Patients With Type 2 Diabetes Mellitus (PHASE4)
- Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015) (PHASE3)
- Efficacy and Safety of Mitiglinide vs Acarbose in Patients With Type 2 Diabetes Mellitus (PHASE4)
- Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes (PHASE4)
- Long-term Study of KAD-1229 in Type 2 Diabetes Patients (PHASE3)
- Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogues in Type 2 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MITIGLINIDE CI brief — competitive landscape report
- MITIGLINIDE updates RSS · CI watch RSS